Shares of Revvity Inc. (NYSE:RVTY – Get Free Report) have been assigned a consensus recommendation of “Hold” from the eighteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. Fourteen analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $116.5714.
Several analysts have weighed in on the stock. Sanford C. Bernstein assumed coverage on shares of Revvity in a research note on Friday, June 26th. They issued a “market perform” rating and a $115.00 price target for the company. KeyCorp lifted their price objective on Revvity from $125.00 to $165.00 and gave the stock an “overweight” rating in a report on Friday, September 4th. TD Cowen reissued a “buy” rating on shares of Revvity in a research note on Wednesday, July 15th. Evercore restated an “outperform” rating on shares of Revvity in a report on Wednesday, August 5th. Finally, Wall Street Zen lowered Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th.
Read Our Latest Research Report on Revvity
Revvity Stock Up 0.1%
Revvity (NYSE:RVTY – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The firm had revenue of $729.69 million during the quarter, compared to analysts’ expectations of $702.96 million. During the same period in the prior year, the business earned $1.18 EPS. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts anticipate that Revvity will post 5.36 EPS for the current fiscal year.
Revvity Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s payout ratio is presently 13.33%.
Hedge Funds Weigh In On Revvity
Hedge funds have recently modified their holdings of the company. New Mexico Educational Retirement Board boosted its stake in shares of Revvity by 1.9% during the fourth quarter. New Mexico Educational Retirement Board now owns 5,416 shares of the company’s stock valued at $524,000 after purchasing an additional 100 shares in the last quarter. Allworth Financial LP lifted its holdings in Revvity by 8.9% during the fourth quarter. Allworth Financial LP now owns 1,275 shares of the company’s stock worth $123,000 after buying an additional 104 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in Revvity by 5.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,074 shares of the company’s stock valued at $231,000 after acquiring an additional 106 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Revvity by 17.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company’s stock valued at $66,000 after acquiring an additional 109 shares in the last quarter. Finally, Angeles Wealth Management LLC increased its holdings in shares of Revvity by 2.0% in the 2nd quarter. Angeles Wealth Management LLC now owns 5,804 shares of the company’s stock valued at $646,000 after acquiring an additional 112 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.
Revvity Company Profile
Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.
The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.
Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.
Further Reading
- Five stocks we like better than Revvity
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
